as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹948.6
Change
-7.35 (-0.77%)
Open
₹962.5
Prev. Close
₹955.95
Day High
₹962.5
Day Low
₹927.8
Volume Analysis
Traded
111,186
Delivered
27,521
Delivery %
24.75%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (2)
- •Low return on equity (1.49%)
- •Low operating margin (4.1%)
Opportunities (1)
- •Strong 3-year revenue growth (22.8%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹999.5 | ₹981.0 | ₹964.8 | ₹946.3 | ₹930.1 | ₹911.6 | ₹895.4 |
| Fibonacci | ₹981.0 | ₹967.74 | ₹959.56 | ₹946.3 | ₹933.04 | ₹924.86 | ₹911.6 |
| Camarilla | ₹958.14 | ₹954.96 | ₹951.78 | ₹946.3 | ₹945.42 | ₹942.24 | ₹939.06 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+19.6%
1 Week
+10.59%
1 Month
+6.96%
3 Months
-5.33%
6 Months
+34.27%
1 Year
+9.07%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
1.18%
Net margin 1.03% × asset turnover 0.77x × equity multiplier 1.49x
Company Overview
Sector
Healthcare
Market Cap
₹5,296 Cr
P/E (TTM)
293.0
ROE
1.49%
Book Value
₹300.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Orchid Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 52/100. The strongest factor is Financial Strength (100/100), while Business Quality (26/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (1.49%); low operating margin (4.1%). FII holding has been falling.
TopFund Score — Fundamentals Quality
52/100 — AverageData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Promoter holding has increased by 4.61% over last quarter.
- −Stock is trading at 2.95 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Tax rate seems low
- −Company has a low return on equity of 6.76% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
QIP monitoring report for Sept 2026 shows no deviation; Jammu facility commercial operations now expected by February 2027.
Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026
Orchid Pharma signs Latin America licensing and supply deal for Exblifep across nine markets; potential USD 80 million.
Board approved enabling resolution on Oct. 20, 2026 to raise up to Rs 600 crore.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 263 | 194 | 207 | 368 | 304 |
| Expenses + | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 269 | 195 | 206 | 338 | 290 |
| Operating Profit | 22 | 23 | 35 | 29 | 32 | 30 | 26 | 28 | -6 | -1 | 2 | 30 | 14 |
| OPM % | 12.1% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.6% |
| Other Income + | 2 | 8 | 8 | 13 | 8 | 8 | 8 | 4 | 12 | 11 | -2 | 8 | 2 |
| Interest | 6 | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 2 | 4 | 3 | 2 | 2 |
| Depreciation | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 11 | 9 | 9 | 11 | 11 |
| Profit before tax | 11 | 20 | 30 | 30 | 28 | 26 | 22 | 19 | -7 | -3 | -12 | 25 | 3 |
| Tax % | 0.0% | 0.0% | 0.0% | -10.27% | -0.53% | 0.0% | 0.0% | -0.21% | 0.0% | 0.0% | 0.0% | 0.0% | 2.64% |
| Net Profit + | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | -6 | -6 | -13 | 26 | 3 |
| EPS in Rs | 2 | 4 | 6 | 7 | 6 | 5 | 4 | 4 | -1 | -1 | -2 | 5 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 40 | 20 | 38 | 3 | 34 | 12 | -1 | 9 | 8 | -13 | -5 | 55 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Expenses + | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 1,247 | 1,185 | 1,029 |
| Operating Profit | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 18.0% | 20.0% | 0.4% | 3.6% | -2.0% | -6.0% | 7.0% | 10.0% | 13.0% | 14.0% | 11.0% | 3.9% | 4.1% |
| Other Income + | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 26 | 15 | 19 |
| Interest | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 13 | 9 | 11 |
| Depreciation | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 42 | 43 | 40 |
| Profit before tax | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 122 | 10 | 12 |
| Tax % | -49.0% | -6.0% | -9.0% | -12.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -3.0% | -8.0% | -2.0% | — |
| Net Profit + | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS in Rs | -23 | -31 | -56 | -40 | 8 | -32 | -29 | 0 | 11 | 18 | 27 | 2 | 2 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | -10 | -50 | -9 | -14 | -12 | -19 | -7 | 24 | 19 | 23 | 71 | -12 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,494 | 1,504 |
| Borrowings + | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 154 | 307 |
| Other Liabilities + | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 414 | 432 |
| Total Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
| Fixed Assets + | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 708 | 692 |
| CWIP | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 414 |
| Investments | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 60 | 67 |
| Other Assets + | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 1,229 | 1,086 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 2,077 | 2,258 |
| Equity Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 15 | 15 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 51 | 126 |
| Cash from Investing Activity + | 1,334 | -1 | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -36 | -277 |
| Cash from Financing Activity + | -597 | -286 | -465 | 33 | 0 | -250 | -165 | -217 | 31 | 167 | 2 | 137 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 17 | -14 |
| Free Cash Flow | 965 | 211 | 392 | 3 | 5 | 77 | 23 | 238 | -8 | 61 | -102 | -255 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -102 | 124 | 13,628 | 67 | -138 | -226 | 63 | 173 | 22 | 113 | 44 | 259 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.52% | 10.47% | 9.82% | 9.94% | 8.63% | 7.37% | 9.34% | 9.57% | 9.61% | 9.04% | 8.62% | 7.17% |
| Promoters | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 74.45% |
| FII | 4.14% | 1.96% | 1.42% | 1.94% | 2.53% | 2.69% | 1.39% | 1.56% | 1.17% | 0.87% | 0.8% | 0.93% |
| DII | 14.51% | 17.73% | 18.93% | 18.3% | 19.0% | 20.1% | 19.43% | 19.04% | 19.38% | 20.24% | 20.75% | 17.44% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Orchid Pharma Limited (this stock) | 5,296 | 293.0 | 2.95 | 1.49% |
| Artemis Med Service Ltd | 5,415 | 46.2 | 5.47 | 12.0% |
| Sahajanand Medical Tech L | 5,427 | 75.6 | — | 10.4% |
| Senores Pharmaceuticals L | 5,125 | 38.4 | 5.11 | 13.4% |
| Morepen Lab. Ltd | 5,061 | 26.8 | 3.67 | 5.33% |
| Iol Chem And Pharma Ltd | 5,587 | 26.4 | 2.91 | 8.41% |
| Sms Pharmaceuticals Ltd. | 4,758 | 40.7 | 5.64 | 14.3% |
Which Mutual Funds Hold Orchid Pharma Limited?
Frequently Asked Questions about Orchid Pharma Limited
Orchid Pharma Limited (ORCHPHARMA) closed at ₹948.6 on NSE on 19 November 2026, down 7.35 (0.77%) from the previous close.
Orchid Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol ORCHPHARMA.
Orchid Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 293.0.
Orchid Pharma Limited has a dividend yield of 0.0%.
Orchid Pharma Limited's 52-week high is ₹1,144.0 and its 52-week low is ₹471.0.
Orchid Pharma Limited has a market capitalisation of ₹5,296 crore.
Orchid Pharma Limited has a TopFund Quality Score of 52/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Orchid Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.